Image showing sections of cerebral brain organoids derived from pluripotent stem cells.
via Agnieszka Rybak-Wolf, MDC/LifeTime
Hundreds of researchers, clinicians, industry leaders and policy makers from all around Europe are united by a vision of how to revolutionize healthcare. In a perspective in Nature and the LifeTime Strategic Research Agenda they now present a roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime.
The LifeTime initiative, co-coordinated by the Max Delbrück Center of Molecular Medicine in the Helmholtz Association (MDC) in Berlin and the Institut Curie in Paris, has developed a strategy to advance personalized treatment for five major disease classes: cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases. The aim is a new age of personalized, cell-based interceptive medicine for Europe with the potential of improved health outcomes and more cost-effective treatment, resulting in profoundly changing a person’s healthcare experience.
Earlier detection and more effective treatment of diseases
To form a functioning, healthy body, our cells follow developmental paths during which they acquire specific roles in tissues and organs. But when they deviate from their healthy course, they accumulate changes leading to disease which remain undetected until symptoms appear. At this point, medical treatment is often invasive, expensive and inefficient. However, now we have the technologies to capture the molecular makeup of individual cells and to detect the emergence of disease or therapy resistance much earlier.
Using breakthrough single-cell and imaging technologies in combination with artificial intelligence and personalized disease models will allow us to not only predict disease onset earlier, but also to select the most effective therapies for individual patients. Targeting disease-causing cells to intercept disorders before irreparable damage occurs will substantially improve the outlook for many patients and has the potential of saving billions of Euros of disease-related costs in Europe.
A detailed roadmap for implementing LifeTime
The perspective article “The LifeTime initiative and the future of cell-based interceptive medicine in Europe” and the LifeTime Strategic Research Agenda (SRA) explain how these technologies should be rapidly co-developed, transitioned into clinical settings and applied to the five major disease areas. Close interactions between European infrastructures, research institutions, hospitals and industry will be essential to generate, share and analyze LifeTime’s big medical data across European borders. The initiative’s vision advocates to benefit citizens all across Europe.
According to Professor Nikolaus Rajewsky, scientific director of the Berlin Institute for Medical System Biology at the Max Delbrück Center for Molecular Medicine and coordinator of the LifeTime Initiative, the LifeTime approach is the way into the future: “LifeTime has brought together scientists across fields – from biologists, to clinicians, data scientists, engineers, mathematicians, and physicists – to enable a much improved understanding of molecular mechanisms driving health and disease. Cell-based medicine will allow doctors to diagnose diseases earlier and intercept disorders before irreparable damage has occurred. LifeTime has a unique value proposition that promises to improve the European patient’s health.”
Dr. Geneviève Almouzni, director of research at CNRS, honorary director of the research center from Institut Curie in Paris and co-coordinator of the LifeTime Initiative believes that the future with LifeTime offers major social and economic impact: “By implementing interceptive, cell-based medicine we will be able to considerably improve treatment across many diseases. Patients all over the world will be able to lead longer, healthier lives. The economic impact could be tremendous with billions of Euros saved from productivity gains simply for cancer, and significantly shortened ICU stays for Covid-19. We hope EU leaders will realize we have to invest in the necessary research now.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cell-based interceptive medicine
- ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants
ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase 1 ...
- Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma
Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based ...
- What Factors Affect the Severity of Permanent Tooth Impaction?
On panoramic radiographs, the impacted teeth were initially ranked based on their vertical ... diagnoses and the planning of preventive or interceptive interventions for young patients.
Go deeper with Google Headlines on:
Cell-based interceptive medicine
Go deeper with Bing News on:
- Kentucky basketball team will hold open practice Tuesday as part of flood relief efforts
The Kentucky basketball team will have an open practice in Rupp Arena on Tuesday, along with a telethon, to help raise money for flood relief.
- The out island adventure of a lifetime
I swam with sharks in the ocean and lived, unscathed, to tell the tale! I snorkeled in and around 96-year-old ship wreck as my summer adventures through the out islands continued with a visit to the ...
- How Do You Build Customer Lifetime Value In A Period Of Reduced Consumption?
At the latest quarterly meeting, they discussed the impact of the crisis on the sector, and what retailers can do to increase customer lifetime value (CLV) and emerge stronger. RTT members focused on ...
- DSF institutes first of its kind Dinesh Shahra Lifetime Award for Excellence in Music
Mumbai Maharashtra [India] July 28 ANIPNN Dinesh Shahra Foundation DSF has taken a major stride in its efforts to promote soulful Indian music among the masses The Foundation has instituted a first-of ...
- US, Canadian initiative aims to accelerate transition to zero-emission trucks
A multistate initiative focused on cutting emissions from medium- and heavy-duty vehicles released an action plan for transitioning to zero-emission vehicles.